Drugs / BB-025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07202663 | Nov 2025 → Mar 2026 | — | Basking Biosciences, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-08-25 | Basking Biosciences, Inc. | Results Basking Biosciences Announces Positive Topline Phase 1 Data for BB-025, the Reversal Agent for its Acute Ischemic Stroke Thrombolytic Therapy BB-031 baskingbiosciences.com ↗
When administered following a single dose of BB-031, BB-025 produced a complete, rapid, and stable reversal of BB-031 activity, restoring vWF activity and platelet function within five minutes |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-25 | Basking Biosciences, Inc. | Basking Biosciences Announces Positive Topline Phase 1 Data for BB-025, the Reversal Agent for its Acute Ischemic Stroke Thrombolytic Therapy BB-031 baskingbiosciences.com ↗ |
| 2025-11-12 | Basking Biosciences, Inc. | Basking Biosciences Announces First Participants Dosed in Phase 1 Study of BB-025, a Direct-Acting Reversal Agent for Investigational Stroke Therapy BB-031 baskingbiosciences.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB-025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07202663 ↗ |